HFO-1234ze(E) + HFA-134a
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mucociliary Clearance
Conditions
Mucociliary Clearance
Trial Timeline
Jun 14, 2023 → Jul 22, 2024
NCT ID
NCT05755932About HFO-1234ze(E) + HFA-134a
HFO-1234ze(E) + HFA-134a is a phase 3 stage product being developed by AstraZeneca for Mucociliary Clearance. The current trial status is completed. This product is registered under clinical trial identifier NCT05755932. Target conditions include Mucociliary Clearance.
What happened to similar drugs?
1 of 1 similar drugs in Mucociliary Clearance were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05755932 | Phase 3 | Completed |
Competing Products
1 competing product in Mucociliary Clearance
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose) | Sumitomo Pharma | Approved | 43 |